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CLC-K channels belong to the CLC gene family, which comprises both Cl− channels and Cl−/
H+ antiporters. They form homodimers which additionally co-assemble with the small protein 
barttin. In the kidney, they are involved in NaCl reabsorption; in the inner ear they are important 
for endolymph production. Mutations in CLC-Kb lead to renal salt loss (Bartter’s syndrome); 
mutations in barttin lead additionally to deafness. CLC-K channels are interesting potential drug 
targets. CLC-K channel blockers have potential as alternative diuretics, whereas CLC-K activators 
could be used for the treatment of patients with Bartter’s syndrome. Several small organic acids 
inhibit CLC-K channels from the outside by binding to a site in the external vestibule of the ion 
conducting pore. Benzofuran derivatives with affinities better than 10 μM have been discovered. 
Niflumic acid (NFA) exhibits a complex interaction with CLC-K channels. Below ∼1 mM, NFA 
activates CLC-Ka, whereas at higher concentrations NFA inhibits channel activity. The co-planarity 
of the rings of the NFA molecule is essential for its activating action. Mutagenesis has led to the 
identification of potential regions of the channel that interact with NFA. CLC-K channels are also 
modulated by pH and [Ca2+]ext. The inhibition at low pH has been shown to be mediated by a His-
residue at the beginning of helix Q, the penultimate transmembrane helix. Two acidic residues 
from opposite subunits form two symmetrically related intersubunit Ca2+ binding sites, whose 
occupation increases channel activity. The relatively high affinity CLC-K blockers may already 
serve as leads for the development of useful drugs. On the other hand, the CLC-K potentiator 
NFA has a quite low affinity, and, being a non-steroidal anti-inflammatory drug, can be expected 
to exert significant side effects. More specific and more potent activators will be needed and it 
will be important to understand the molecular mechanisms that underlie NFA activation.
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tion pathway (“double-barreled channel”) (see Figure 3A); even 
though some CLC proteins require small β-subunits (barttin and 
ostm1) for proper function (Estévez et al., 2001; Waldegger et al., 
2002; Lange et al., 2006), the basic mechanisms of ion conduction 
are mostly dependent of the CLC α-subunits. So far all CLC proteins 
that have been functionally investigated, appear to be impermeable 
to cations (except protons, see below). The open probability (P
o
) of 
the CLC channels is regulated by two distinct gating mechanisms: 
a “protopore gate” or “fast gate” (in CLC-0) closes individual pores 
and an additional, slow (or common) gate closes both pores simul-
taneously. It is still unclear whether similar gating mechanisms are 
present also in CLC transporters, like the human CLC-5 Cl−/H+ 
antiporter or the plant CLC-a NO
3
−/H+ antiporter (De Angeli et al., 
2006, 2009; Zdebik et al., 2008; Alekov and Fahlke, 2009; Zifarelli 
and Pusch, 2009b; Picollo et al., 2010).
Important structural and functional information was pro-
vided by the crystal structures of bacterial CLCs (Dutzler et al., 
2002, 2003). Each monomer consists of 18 intramembrane 
α-helices (labeled A-R) and exhibits a complex topology. Each 
subunit presents an internal pseudo-two-fold symmetry with 
the two halves spanning the membrane in opposite directions. 
Each subunit bears three distinct Cl− binding sites which can be 
occupied simultaneously, called S
int
, S
cen
, S
ext
 (Dutzler et al., 2002, 
2003; Lobet and Dutzler, 2006; Picollo et al., 2009). In the crystal 
IntroductIon
CLC proteins form a family of voltage-gated Cl− channels and 
Cl−/H+-exchangers involved in important physiological processes, 
including transepithelial transport, membrane excitability, cell vol-
ume regulation, and luminal acidification of the endosomal–lyso-
somal system (Zifarelli and Pusch, 2007). Knockout mouse models 
and human diseases have provided insights into the physiologic 
role of CLC proteins. Mutations in four of the nine human CLC 
genes underlie inherited diseases. CLC-1 mutations cause myoto-
nia; mutations in CLC-Kb and in BSDN, the gene codifying barttin, 
determine different forms of Bartter’s syndrome with renal salt 
loss; CLC-5 mutations are responsible for Dent’s disease; muta-
tions of CLC-7 lead to osteopetrosis (Zifarelli and Pusch, 2007; 
Jentsch, 2008).
Kidney and inner ear specific CLC-K channels are particularly 
interesting potential drug targets. In the present review, after pro-
viding a brief overview over CLC proteins in general and CLC-K 
channels in particular, we will review in detail the current knowl-
edge on the interaction of CLC-K channels with various organic 
and inorganic ligands.
All CLC proteins share several basic features. Structurally, they 
share the same homodimeric architecture (Ludewig et al., 1996; 
Middleton et al., 1996; Weinreich and Jentsch, 2001), in which each 
of two identical subunits contains an independent anion permea-
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CLC proteins are expressed in many organs, yet the kidney is the 
preferential expression site for several CLC channels and exchang-
ers. In fact the physiological functions of this organ require a match-
ing system of transporters targeted specifically to the apical or the 
basolateral membranes. In particular, a large fraction of NaCl and 
cation reabsorption happens at the level of Henle’s loop of the 
nephron. In the thick ascending limb (TAL) the concerted action 
of the Na/K-ATPase, an apical Na–K–2Cl co-transporter, an apical 
K+ recycling channel, and basolateral CLC-Kb/barttin Cl− channels 
mediates NaCl reabsorption (Figure 1A).
Human CLC-Ka and CLC-Kb share 90% of identity whereas 
they are 80% identical to rat CLC-K1 and CLC-K2 (Uchida et al., 
1993; Kieferle et al., 1994). CLC-K channels are expressed in the 
kidney and in the inner ear and co-assemble with the β-subunit 
barttin (Birkenhäger et al., 2001; Estévez et al., 2001). CLC-K1 is the 
only CLC-K channel that is functional without barttin upon het-
erologous expression (Uchida et al., 1993; Waldegger and Jentsch, 
2000; Estévez et al., 2001). Barttin not only enhances trafficking 
from the endoplasmic reticulum to the plasma membrane but also 
affects the processes of permeation and gating of CLC-K channels 
(Scholl et al., 2006; Fischer et al., 2010; Lang, 2010).
CLC-K2 (CLC-Kb) is expressed in basolateral membranes of 
several nephron segments (TAL, connecting tubule, distal convo-
luted tubule, and intercalated cells), whereas CLC-K1 is expressed 
in both apical and basolateral membranes of the thin ascending 
limb of Henle’s loop (Uchida et al., 1995; Vandewalle et al., 1997; 
Matsumura et al., 1999; Estévez et al., 2001; Kobayashi et al., 2001, 
2002). The fact that CLC-K1 is also found on apical membranes 
might be related to its ability to function without barttin. CLC-K 
channels are found in the inner ear also, in the basolateral mem-
branes of marginal cells of the stria vascularis and in dark cells of 
the vestibular organ, where they are involved in the endolymph 
production (Estévez et al., 2001; Rickheit et al., 2008; Zdebik et al., 
structure of CLC-ec1, S
ext
 was found to be occupied by the side 
chain of the conserved glutamate 148. When E148 was mutated 
to alanine or glutamine the same site was occupied by a Cl− ion 
and the ion conduction pathway was open (Dutzler et al., 2003). 
In fact, in most CLC proteins, selective conduction and gating 
are intimately coupled: the permeant ions directly affect gating 
(Pusch et al., 1995) and the critical E148 is the main determinant 
of the “fast gate” (Dutzler et al., 2003). Interestingly, in contrast 
to most CLC channels and CLC transporters, CLC-K channels 
have a hydrophobic residue (valine) in place of the critical gluta-
mate (Waldegger and Jentsch, 2000; Zifarelli and Pusch, 2007; 
Jentsch, 2008).
The common characteristics of CLC proteins initially led to 
the implicit assumption that the family is composed of only 
Cl− channels. Surprisingly, Accardi and Miller (2004) discovered 
that CLC-ec1 is a Cl−/H+ exchanger. Subsequent studies have 
shown that also several eukaryotic CLC proteins are anion/pro-
ton antiporters (Picollo and Pusch, 2005; Scheel et al., 2005; 
De Angeli et al., 2006; Neagoe et al., 2010), demonstrating that 
two different transport mechanisms can be based on the same 
molecular architecture.
In contrast to the bacterial CLC-ec1, all eukaryotic and some 
prokaryotic CLC proteins have large C-terminal intracellular 
domains which bear two so-called CBS domains (Estévez and 
Jentsch, 2002). These domains have been found to bind adenine 
nucleotides in isolated CLC-5 and CLC-2 C-terminals fragments 
(Scott et al., 2004; Wellhauser et al., 2006; Meyer et al., 2007) and 
adenine nucleotides affect the function of CLC-1 (Bennetts et al., 
2005, 2007; Tseng et al., 2007), CLC-5 (Zifarelli and Pusch, 2009b), 
and the plant atCLC-a (De Angeli et al., 2009). However, the CBS 
domains of CLC-Ka do not appear to bind nucleotides (Markovic 
and Dutzler, 2007), and no consistent effects of intracellular nucle-
otides on CLC-K function have been described so far.
Figure 1 | Transport models for NaCl reabsorption in the TAL (A) and for transepithelial K+ transport in the inner ear (B). (A) Schematic representation of an 
epithelial cell from the thick ascending limb of Henle’s loop. All transporters involved in NaCl reabsorption are drawn in different colors. (B) Schematic representation 
of marginal cell from the stria vascularis (for simplicity other epithelial cell layers are not shown). See text for details.
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was also effective on wild-type CLC-K1 co-expressed with barttin 
with a similar apparent K
D
 of ∼100 μM (Liantonio et al., 2002). 
Interestingly, GF-100 was highly effective also on CLC-1, but only 
when applied from the inside, whereas it had almost no effect on 
CLC-K1 from the intracellular side (Liantonio et al., 2002).
Following this pioneering work, Liantonio et al. (2004) per-
formed a structure–activity relationship (SAR) analysis based on 
the GF-100 molecule, using rat CLC-K1 co-expressed with barttin. 
Among several molecules, the simplest structure compatible with 
an elevated blocking potency (K
D
 ∼100 μM) was 3-phenyl-CPP 
(Figure 2C) (Liantonio et al., 2004). Furthermore, it was found 
that the block had a rapid onset and was quickly reversible, dem-
onstrating that the binding site must be exposed to the extracel-
lular side of the channel. The block by 3-phenyl-CPP was slightly 
voltage-dependent and was significantly increased in low [Cl]
ext
 
(Liantonio et al., 2004). This finding suggested that the binding site 
is located in or close to the Cl− ion conducting pathway. Among sev-
eral “classical” Cl− channel blockers, CLC-K1 was found to be quite 
sensitive to extracellular application of 5-nitro-2-(3-phenylpro-
pylamino)benzoic acid (NPPB, K
D
 ∼230 μM), niflumic acid (NFA, 
K
D
 ∼250 μM), and 4,4′-Diisothiocyanato-2,2′-stilbenedisulfonic 
acid (DIDS, K
D
 ∼150 μM) (Liantonio et al., 2004). However, data 
on DIDS inhibition have to be interpreted with caution because 
the DIDS molecule is unstable in aqueous solution (see below).
A pore-blockIng 3-phenyl, dIdS, And benzofurAn 
bIndIng SIte
The initial pharmacological studies employed the rat CLC-K1 
homolog co-injected with barttin which manifests an elevated func-
tional expression level in Xenopus oocytes. In following studies it 
was found that the human homolog CLC-Ka, co-expressed with 
barttin, showed a similar sensitivity to 3-phenyl-CPP (Figure 2C) 
and DIDS (Figure 2F) as the rat CLC-K1 with apparent K
D
 values of 
80 and 90 μM, respectively (Picollo et al., 2004). Surprisingly, human 
CLC-Kb, despite a more than 90% sequence identity with CLC-Ka, 
was significantly less sensitive to both compounds (apparent K
D
 
about five-fold larger, Figure 4A) (Picollo et al., 2004). By compar-
ing the sequences of CLC-K1, CLC-Ka, and CLC-Kb, and based on 
the structure of bacterial CLC homologs (Dutzler et al., 2002, 2003) 
four residues of helix B (Figure 4B) were selected as candidates that 
are responsible for the differential block of CLC-Ka and CLC-Kb by 
3-phenyl-CPP and DIDS (Picollo et al., 2004). In fact, the amino acid 
at position 68, a negatively charged Asp in the less sensitive CLC-Kb 
and a neutral Asn in the sensitive CLC-Ka, was found to be the major 
determinant of 3-phenyl-CPP sensitivity (Figures 4B,C) (Picollo 
et al., 2004). The amino acid at position 72, a negatively charged Glu 
in the less DIDS sensitive CLC-Kb and a neutral Gly in the DIDS 
sensitive CLC-Ka, was found to be additionally important for DIDS 
sensitivity (Picollo et al., 2004). Residue D/N68 is localized in the 
putative extracellular vestibule of the channel, in agreement with 
the notion of a pore-blocking mechanism (colored red in Figure 3). 
However, details of this blocking mechanism remain to be inves-
tigated. Most CLC proteins carry a negatively charged amino acid 
at the equivalent position and mutation of the respective residue 
rather drastically alters functional properties (Fahlke et al., 1995; 
Ludewig et al., 1997; Picollo et al., 2004) and can lead to myotonia 
in the case of CLC-1 (Heine et al., 1994).
2009). Several transporters contribute to maintain a high K+ con-
centration of the endolymph and its positive potential of ∼80 mV 
with respect to normal extracellular space. Both factors (high [K+], 
and high potential) are essential for the stimulation of hair cells 
and the sound transmission in the ear (Figure 1B). A recent study 
(Rickheit et al., 2008), using mice in which barttin was deleted in 
the inner ear but not in the kidney, showed that while [K+] and 
fluid secretion were maintained, the endocochlear potential was 
reduced. This drastic decrease reduces the driving force for K+ entry 
into hair cells and causes deafness in Bartter’s syndrome type IV 
(Rickheit et al., 2008).
The renal diseases associated with mutations in the genes cod-
ing for CLC-Ks and barttin underscore the physiological role of 
these channels. Mutations in CLC-Kb and barttin cause Bartter’s 
syndrome (type III and type IV, respectively), a kidney disease char-
acterized by renal salt wasting due to a reduced NaCl reabsorption 
in the TAL (Simon et al., 1997). Additional deafness is present in 
Bartter’s syndrome type IV (Birkenhäger et al., 2001). Diseases asso-
ciated with CLC-Ka mutations are not known, but simultaneous 
mutations in CLC-Ka and CLC-Kb lead to Bartter’s syndrome (type 
IV) with deafness (Schlingmann et al., 2004). Moreover, mice lack-
ing CLC-K1 exhibit nephrogenic diabetes insipidus (Matsumura 
et al., 1999), suggesting a role for CLC-K1 and, possibly CLC-Ka, 
in the urine concentrating mechanism (Matsumura et al., 1999). 
CLC-Kb polymorphisms have been involved in high blood pressure 
(Jeck et al., 2004). However, subsequent studies were in conflict with 
these results (Kokubo et al., 2005; Speirs et al., 2005).
Specific modulators of CLC-K channels could be useful in the 
treatment of several pathological conditions. For example CLC-Ka 
block, increasing water diuresis, might reduce cardiac load after 
heart failure (Fong, 2004; Picollo et al., 2004). On the other hand, 
CLC-Ka potentiators may be useful in patients with Bartter’s syn-
drome with residual activity of CLC-K channels (Zifarelli et al., 
2010). Because there is no information on the functional properties 
of the rat CLC-K2 channel, we limit our review on the data that have 
been obtained for rat CLC-K1 and the two human isoforms.
the dIScovery of bIS-phenoxy derIvAtIveS of cpp AS 
blockerS of clc-k chAnnelS
Before the discovery of barttin as an essential β subunit of CLC-K 
channels (Estévez et al., 2001), only the rat CLC-K1 could be func-
tionally expressed in heterologous systems (Uchida et al., 1993). 
However, the expression level was too low to allow a detailed phar-
macological characterization. To overcome this limitation and to 
explore the functional properties of the human CLC-K homologs, 
Waldegger and Jentsch (2000) constructed chimeras between rat 
CLC-K1 and human CLC-Kb. One of these chimeras was used by 
Liantonio et al. (2002) in an early pharmacological investigation. 
These authors tested various derivatives of CPP (p-chlorophenoxy-
propionic acid) (Figure 2A) as potential CLC-K inhibitors. CPP, 
a blocker of the skeletal muscle Cl− conductance (De Luca et al., 
1992), had previously been shown to block CLC-0 and CLC-1 from 
the intracellular side (Aromataris et al., 1999; Pusch et al., 2000). 
While CPP itself was ineffective (from the outside), bis-phenoxy 
derivatives of CPP (e.g., GF-100, Figure 2B) were shown to be 
relatively potent inhibitors of the CLC-K chimera when applied 
from the outside (K
D
 ∼100 μM) (Liantonio et al., 2002). GF-100 
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tools to probe the channel function and structure, they are  probably 
rather useless from a pharmacological point of view, because of 
their chemical reactivity.
Recently, benzofuran derivatives of 3-phenyl-CPP were found to 
block CLC-K channels with greatly improved potency compared to 
3-phenyl-CPP (Liantonio et al., 2008). The two most potent mol-
ecules were MT-189 (Figure 2I) and RT-93 (Figure 2J) with appar-
ent K
D
 values of 7 μM. Both compounds had a significantly reduced 
potency on the CLC-Ka-N68D mutant, suggesting that they bind to 
the same site as 3-phenyl-CPP and DIDS (the residue correspond-
ing to N68 is colored in red in Figure 3). In line with this finding, 
compound MT-189 had also a reduced affinity for CLC-Kb (appar-
ent K
D
 ∼20 μM). Interestingly, the more hydrophobic compound 
RT-93 was equally effective on CLC-Kb (apparent K
D
 ∼6 μM) as on 
Regarding the effect of DIDS on CLC-K channels it has to be 
noted that Matulef et al. (2008) reported that the DIDS molecule 
itself (Figure 2F) is rather unstable in aqueous solutions and that 
by virtue of the reactivity of DIDS, higher order “DIDS oligomers” 
can form. Some of these oligomers have a highly increased potency 
of block of CLC-Ka with K
D
 values of the order of a few micromolar 
(Matulef et al., 2008). Block was drastically reduced by the N68D 
mutation suggesting that the DIDS oligomers bind to the same 
site as the DIDS monomer. The high affinity of “DIDS tetramers” 
or “DIDS pentamers” is consistent with the hypothesis that the 
two ends of these long molecules bind each in one of the pores 
of the homodimeric channel (Matulef et al., 2008). These oligo-
meric DIDS molecules are so far the most potent CLC-K blockers. 
However, even though these molecules are highly interesting as 
Figure 2 | Chemical structures of various substances that inhibit or activate CLC-K channels. (A) CPP (p-chlorophenoxy-propionic acid); (B) GF-100 (proper 
name); (C) 3-Ph-CPP (3-phenyl-CPP); (D) NFA (niflumic acid); (e) FFA (flufenamic acid); (F) DIDS (4,4′-Diisothiocyanato-2,2′-stilbenedisulfonic acid); (g) Triflocin; 
(H) GF-166 (proper name); (i) MT-189 (proper name); (J) RT-93 (proper name).
www.frontiersin.org October 2010 | Volume 1 | Article 130 | 5
Gradogna and Pusch Pharmacology of CLC-K chloride channels
because the mutant CLC-Ka-N68 was much less sensitive to FFA 
(Liantonio et al., 2006). However, the block of CLC-Ka by NFA 
at higher concentrations (Figure 5B) and the block of CLC-K1 
by NFA (Figure 5A) is probably not mediated by the same bind-
ing site, because it is unaltered by the N68D mutation (Picollo 
CLC-Ka (Liantonio et al., 2008). This compound represents thus 
the most potent blocker of CLC-Kb described so far. In addition, 
this result suggests that it is probably difficult to develop drugs that 
are highly specific for one of the human CLC-K homologs.
ActIvAtIon And block by fenAmAteS
Niflumic acid (Figure 2D) and flufenamic acid (FFA) (Figure 2E) 
belong to a class of fenamates usually used as non-steroidal anti-
inflammatory drugs. However, in particular NFA, is also known 
as a classical Cl− channel inhibitor. In fact, CLC-K1 was found to 
be blocked by NFA with an apparent K
D
 of ∼100 μM (Liantonio 
et al., 2004; Picollo et al., 2007) (Figure 5A). It was therefore rather 
surprising that the human CLC-K homologs are activated rather 
than blocked by sub-millimolar concentrations of NFA (Liantonio 
et al., 2006). CLC-Ka is blocked by higher concentrations (above 
∼1 mM) of NFA leading to a biphasic concentration depend-
ence (Figure 5B). In contrast, CLC-Kb is potentiated by NFA 
at all concentrations tested (Liantonio et al., 2006) (Figure 5C). 
Currents start to increase within a few seconds after application 
of NFA strongly suggesting that the respective binding site is 
located on the extracellular face of the protein (Liantonio et al., 
2006; Picollo et al., 2007). Interestingly, flufenamic acid (FFA, 
Figure 2E), whose structure seems to be very similar to that of 
NFA (see Figures 2D,E), does not activate CLC-Ka, but rather 
induces channel block. The FFA block is probably mediated by 
the same pore binding site as 3-phenyl-CPP block (see above) 
Figure 3 | Binding sites on CLC-K channels. In (A) a view from the outside 
of the bacterial CLC-ec1 (pdb code 1OTS) homodimer is shown with one 
subunit in cartoon and the other in surface representation. In (B) a zoom of a 
selected region highlighting the residues involved in ligand binding. Cl− ions in 
pink; gating glutamate in blue; N68 implicated in block by CPP in red (D54 in 
CLC-ec1); H497 mediating H+ block in yellow (L421 in CLC-ec1); E261 and 
D278 forming the Ca binding site in cyan (E235 and N250 in CLC-ec1); L155, 
G345, and A349 which are important for NFA potentiation in orange (L139, 
T312, and G316 in CLC-ec1).
Figure 4 | effect of 3-phenyl-CPP on CLC-Ka, CLC-Kb, and mutants. (A) 
The blocking effect of 3-phenyl-CPP is schematically indicated for CLC-Ka and 
CLC-Kb. (B) A sequence alignment of a short stretch of residues of helix B of 
CLC-Ka, CLC-Kb, CLC-K1, and StCLC, a bacterial homolog (Dutzler et al., 
2002) is shown. Residues which are identical in CLC-Ka and CLC-K1, and 
different in CLC-Kb, are underlined. CLC-K residues at position 68 drastically 
affect block by 3-phenyl-CPP. DIDS block is additionally dependent on the 
residue at position 72. Sequence of the bacterial StCLC is shown because the 
mutagenesis work was guided by the crystal structure of this protein. 
Residues at positions 68 and 72 are mostly responsible for the difference 
between CLC-Ka and CLC-Kb and are shown in bold. (C) Schematically the 
blocking effect of 3-phenyl-CPP of mutants CLC-Ka-N68D and CLC-Kb-D68N. 
Plots were generated based on data from Picollo et al. (2004).
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The striking difference between the effects of NFA (activating) 
and FFA (blocking) on CLC-Ka could be explained by a funda-
mental difference between these two molecules: NFA has a rather 
rigid structure in which the aromatic rings are strictly co-planar. In 
contrast, in FFA, lacking the N-atom in the COOH-bearing ring, 
the H-atom of the C corresponding to the N of NFA induces a steric 
hindrance that disturbs the co-planarity (Liantonio et al., 2006). 
Similarly, also 3-phenyl-CPP has a flexible, non-co-planar confor-
mation. This hypothesis (Liantonio et al., 2006) was nicely con-
firmed by designing a “flexible, non-co-planar version” of NFA, and 
similarly by designing a “rigid, co-planar version” of FFA (Liantonio 
et al., 2008). Triflocin differs from NFA only in the position of the 
pyridine N (Figure 2G) but the H-atom at the ortho position now 
induces the same steric hindrance as in FFA. In agreement with the 
above mentioned hypothesis, triflocin induces block of CLC-Ka at 
all concentrations tested (Liantonio et al., 2008). On the other hand, 
the “co-planar FFA”, in which the two phenyl groups are forced 
to assume a co-planar conformation by a cyclization (molecule 
GF-166, Figure 2H), showed an activating effect on CLC-Ka at 
concentrations below 200 μM (Liantonio et al., 2008).
Niflumic acid activates CLC-Ka and CLC-Kb by increasing the 
probability of the channel to be in the open state. In fact, the basal 
P
o
 of CLC-Ka and CLC-Kb is small, i.e., at least smaller than about 
0.1 (Picollo et al., 2007; Gradogna et al., 2010; Zifarelli et al., 2010). 
This small basal P
o
 provides a large margin for the activation by 
various ligands. It is not clear, however, which is the molecular 
mechanism that underlies the regulation of the open-probability 
of CLC-K channels. In a first attempt to obtain more insight into 
the molecular mechanism of NFA effects on CLC-Ka, Picollo et al. 
(2007) separated the blocking effect of NFA from the potentiating 
effect and concluded that probably two NFA molecules have to 
bind in order to induce channel closure, whereas binding of one 
NFA molecule suffices to induce potentiation.
In an attempt to identify the NFA binding site(s), Zifarelli et al. 
(2010) functionally screened about 80 mutations of CLC-Ka, test-
ing for the activating effect of 200 μM. They could identify two 
regions of the protein which are distant on the primary sequence 
but relatively close in the 3D structure. The three amino acids which 
abolished the activating effect of NFA were L155, G345, and A349, 
and are colored orange in Figure 3. However, in that work, it could 
not be excluded that these residues are not involved in NFA binding 
but rather in transmitting the binding event to the resulting change 
in P
o
. Further work is clearly necessary in order to understand better 
the complex interaction of NFA with CLC-K channels.
regulAtIon by ca And ph
Previous studies demonstrated in several models that CLC-K 
channels are enhanced by increasing of extracellular Ca2+ (Uchida 
et al., 1995; Sauvé et al., 2000; Waldegger and Jentsch, 2000; 
Estévez et al., 2001; Waldegger et al., 2002) (Figure 6B). Such a 
regulation by divalent cations has not been found in other mem-
bers of the CLC family. Moreover, CLC-K channels are blocked 
by acid pH (Uchida et al., 1995; Sauvé et al., 2000; Waldegger 
and Jentsch, 2000; Estévez et al., 2001; Waldegger et al., 2002) 
(Figure 6A). Proton modulation is common in CLC proteins both 
in Cl−/H+ antiporters as well as in most of the channels (Friedrich 
et al., 1999; Accardi and Miller, 2004; Picollo and Pusch, 2005; 
et al., 2007). CLC-Kb appears somewhat more susceptible to the 
potentiating effect of fenamates in that also FFA enhances cur-
rents (Liantonio et al., 2006) (Figure 5C).
Figure 5 | Blocking and potentiating effects of NFA and FFA on various 
CLC-K homologs (A: CLC-K1, B: CLC-Ka, C: CLC-Kb). The effect of NFA is 
schematically drawn in black, whereas the effect of FFA is shown in red. No 
measurements with FFA on CLC-K1 have been reported.
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mutation in the C-terminus altered Ca2+ sensitivity of CLC-Kb 
(but not CLC-Ka) probably by an indirect effect (Martinez and 
Maduke, 2008).
Gradogna et al. (2010) performed a biophysical analysis of Ca2+ 
and proton modulation of human CLC-K channels expressed in 
Xenopus oocytes. Kinetic experiments, performed by patch record-
ings and fast solution exchange, showed an allosteric modulation of 
CLC-Ka for both, Ca2+ and protons (Gradogna et al., 2010). It was 
demonstrated that Ca2+ and protons act via independent mecha-
nisms and binding sites (Gradogna et al., 2010). Modeling predicted 
a two state (blocked/unblocked) mechanism with a pK = 7.1 for 
proton modulation and it was suggested two protons are neces-
sary to block the channel. Because Ca2+ is not strictly essential 
for opening, a four-state mechanism was used for modeling the 
Ca2+-dependence, with Ca2+ binding constants of KO = 1.5 mM for 
the open state and KC = 19.6 mM for the closed state (Gradogna 
et al., 2010).
To identify the Ca2+ binding site, all charged and titratable 
residues accessible from the extracellular side were mutated. This 
extensive mutagenesis led to the identification of two mutations, 
E261Q and D278N, that reduced calcium sensitivity of CLC-Ka. 
E261 and D278 from different subunit are close to each other and 
likely form an intersubunit Ca2+ binding site; in fact the double 
mutant E261Q/D278N completely abolished modulation by cal-
cium (Gradogna et al., 2010). The corresponding residues are 
colored cyan in Figure 3.
Recently Niemeyer et al. (2009) identified an off-pore histidine 
as being responsible for the proton induced block of the CLC-2 
channel. Based on this discovery, the corresponding residue of 
CLC-Ka, H497, was mutated in several amino acids (Gradogna 
et al., 2010). The only functional mutant H497M showed very small 
currents. Interestingly, the triple mutant E261Q/D278N/H497M 
yielded bigger currents than H497M and completely abolished 
proton block. This result suggested that the same mechanism con-
trols proton block of CLC-2 and CLC-K channels (Gradogna et al., 
2010). The residue His-497, at the beginning of helix Q is colored 
yellow in Figure 3. Both Ca2+ and H+ act by altering the P
o
 of the 
channel. However, it is unclear if they affect the same or different 
gating processes.
poSSIble ApplIcAtIonS of clc-k chAnnel ActIvAtorS 
And InhIbItorS And generAl outlook
CLC-K channels are highly promising drug targets. Firstly, block-
ers of CLC-K channels are promising alternative diuretics (Fong, 
2004). Secondly, pharmacological tools can be used in cellular or 
animal models in order to explore the physiological role of CLC-Ks. 
Third, activators of CLC-K channels may be useful for patients with 
Bartter’s syndrome by activating the available CLC-Ka channels or 
by increasing residual CLC-Kb channel activity.
However, since CLC-K channels are also necessary for the gen-
eration of a positive endocochlear potential (Rickheit et al., 2008), 
side effects of any CLC-K specific drug have to be carefully evalu-
ated. In this respect it is interesting to note that recessive loss of 
function of CLC-Kb leads to Bartter’s syndrome without deafness, 
presumably because of sufficient CLC-Ka function in the inner 
ear. Thus, drugs that specifically block CLC-Kb, but not CLC-Ka, 
might avoid such side effects. The same may be true for CLC-Ka 
Zifarelli and Pusch, 2009a). Interestingly, CLC-K channels are 
lacking the “critical glutamate” whose protonation/deprotona-
tion is involved in the opening of most CLC channels (Hanke 
and Miller, 1983; Rychkov et al., 1996; Jordt and Jentsch, 1997; 
Chen and Chen, 2001; Arreola et al., 2002; Dutzler et al., 2003; 
Traverso et al., 2006; Zifarelli et al., 2008; Niemeyer et al., 2009; 
Zifarelli and Pusch, 2010). This suggested that a different mecha-
nism of pH regulation is present in CLC-K channels. Since the 
kidney is involved in calcium reabsorption and the maintenance 
of acid-base balance (Frick and Bushinsky, 2003; Jeck et al., 2005), 
Ca2+ and proton regulation of CLC-K channels is potentially of 
physiological relevance.
The CLC-Kb mutation, R351W, found in patients with Bartter’s 
syndrome, was reported to abolish Ca2+ activation and to reduce 
the pH effect in CLC-Kb (Yu et al., 2009). However, the currents 
mediated by the mutant CLC-Kb construct were barely above 
background, and similar mutations in CLC-Ka had no effect 
on Ca2+ or H+ sensitivity (Gradogna et al., 2010). Similarly, a 
Figure 6 | effects of extracellular pH (A) and [Ca2+] (B) on WT CLC-Ka 
(black line) and the mutants (red lines) e261Q/D278N/H497M (A) and 
e261Q/D278N (B) schematically drawn according to the results of 
gradogna et al. (2010).
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